Skip to main content
Caplight Logo









eMed

eMed

Private
Miami, FloridaHealthcare & Life Scienceshttps://emed.com/

Last Round

Series A

Mar 26, 2026

Est. Valuation

$2B

Total Funding Raised

$200M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

eMed is a healthtech company that provides a digital health platform offering telehealth services, at-home diagnostics, and clinically managed GLP-1 weight management programs for employers and individuals.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, Medical Devices, Patient Engagement

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS, Subscription SaaS

AI Layer

Application

Keywords

telehealthat-home diagnostic testingremote clinical consultationvirtual carepopulation health managementdigital healthGLP-1 managementpoint-of-care testingPOCTpatient monitoringadherence trackingtelemedicineclinical proctoringdigital health platformemployer health benefitsvirtual clinic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

eMed Comparables

Compare eMed with similar companies based on industry and business-model similarity.

eMed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Everly Health
83%
LetsGetChecked
80%
Fuze Health
74%

eMed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 26, 2026

Key People

Founding team and executive leadership

Jim Heising

Chief Technology Officer

Executive Team

eMed Investors

Notable investors and investment history

eMed investors
InvestorRounds
Knighthead Capital ManagementSeries A
Paragon BiosciencesSeries A
8VCSeries A
Valor Equity PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 129% MoM, reaching 299.1K.

  • Aug 1, 2026

    Open roles increased to 158, 56% of headcount.

eMed Filings

Explore SEC and related filing metadata, where available.

eMed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about eMed's valuation, stock price, and market status.

Is eMed a public or private company?

eMed is a private company.

What is the current stock price of eMed?

eMed is a private company with no public stock price. No recent secondary market data is available.

How much is eMed worth (valuation)?

eMed's valuation is estimated at $2.0B based on funding round data.

Can I buy eMed stock?

eMed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was eMed's last funding round?

eMed's most recent funding round was Series A on March 26, 2026.

Who are the main investors in eMed?

Key investors in eMed include Knighthead Capital Management, Paragon Biosciences, 8VC, Valor Equity Partners.

Will eMed IPO soon?

No public IPO plans have been announced for eMed.

How can I track eMed secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor eMed's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMiami, Florida
Employee Range142
Year Founded2020
Last FundingMar 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?